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from 164 patients (66%, mean age [SD]: 60 [7] years, 81% female, mean
BMI [SD]: 27 [5] kg/m2). Fifety-ﬁve patients showed hand OA progression.
BMI was positively correlated with leptin (Pearson’s correlation coeﬃcient,
r=0.3) and resistin (r=0.2) and negatively correlated with adiponectin
(r=-0.2). Leptin, adiponectin and resistin did not signiﬁcantly correlate to
each other. BMI was not associated with radiographic hand OA progression
(β-regression coeﬃcient -0.04 (95% conﬁdence interval -0.08 to 0.05). The
association between adipokines and progression of osteoarthritis is shown
in Table 1.
Table 1. Association between adipokines and progression of hand osteoarthritis
Adiponectin Risk Ratio (95% CI) Risk Ratio (95% CI) after
adjustment for age, sex, BMI and family effect
Leptin (ng/mL)
<4.4 1 (reference) 1 (reference)
4.41 to 8.2 0.7 (0.3 to 1.6) 0.7 (0.3 to 1.5)
>8.2 1.1 (0.5 to 2.3) 1.2 (0.4 to 2.5)
Adiponectin (μg/mL)
<16.6 1 (reference) 1 (reference)
16.6 to 28.4 0.3 (0.1 to 0.7) ‡ 0.2 (0.1 to 0.5) ‡
>28.4 0.3 (0.1 to 0.6) ‡ 0.2 (0.1 to 0.5) ‡
Resistin (ng/mL)
<0.8 1 (reference) 1 (reference)
0.8 to 1.4 1.0 (o.4 to 2.1) 0.9 (0.4 to 1.8)
>1.4 0.8 (0.4 to 1.7) 0.7 (0.3 to 1.5)
CI: Conﬁdence Interval.
Conclusions: We show for the ﬁrst time a substantial inverse association
between serum adiponectin levels and radiographic worsening of hand
osteoarthritis. Further studies on the use of adiponectin as biological
markers for osteoarthritis progression and studies on the biological role of
adiponectin in osteoarthritis are needed.
116
SERUM BIOMARKER STUDIES OF SYMPTOMATIC SUBJECTS WITH
PERSISTENT KNEE PAIN, WITH ANDWITHOUT OA, REVEAL SIGNIFICANT
DIFFERENCES FROM ASYMPTOMATIC SUBJECTS IN SYSTEMIC MARKERS
OF INFLAMMATION SUGGESTING DIFFERENCES IN INNATE IMMUNITY
J. Cibere1, F. Baribaud2, K. Ma2, E.C. Sayre1, N. Prestley3, H. Wong1,
A. Thorne1, J. Singer1, A.R. Poole4, J.A. Kopec1, A. Guermazi5, S. Nicolaou1,
J.M. Esdaile1
1Univ. of British Columbia, Vancouver, BC, Canada; 2Centocor Res. and Dev.
Inc, Radnor, PA; 3Arthritis Res. Ctr. of Canada, Vancouver, BC, Canada; 4McGill
Univ., Montreal, QC, Canada; 5Boston Univ. Med. Ctr., Boston, MA
Purpose: To contrast serum biomarker levels in population-based cohorts
asymptomatic for knee pain and symptomatic for knee pain.
Methods: Subjects, 40-79 years, with knee pain (n=255) were recruited
as a random population sample in a study to evaluate early knee os-
teoarthritis (OA) (MoDEKO study). Subjects, 40-79 years, without knee
pain (n=80) were recruited as a random sample of the same population.
For the symptomatic cohort, subjects were included if, in at least one
knee, they had 1) pain in or around the knee on most days of the
month at any time in the past; and, 2) any pain in or around the knee
during the past year. In the asymptomatic cohort, subjects were included
if they responded ‘no’ to both pain questions for both knees. OA status
was assessed on magnetic resonance imaging (MRI) (1.5T) with cartilage
graded from 0-4 (0=normal, 1=hyperintense signal, 2=less than 50% defect,
3=50-100% defect, 4=100% defect). Twenty-three serum biomarkers were
measured in both cohorts, including matrix metalloproteinases (MMPs) 1,
3 and 9, tissue inhibitor of MMP (TIMP-1), interleukins (IL) 1a, 1b, 4, 6,
7, 8, 10, 17A, tumor necrosis factor alpha, c-telopeptide of type I collagen
(CTX-I), adiponectin, resistin, eotaxin, C-reactive protein (CRP), hyaluronic
acid (HA), cartilage oligomeric matrix protein (COMP) and chemokines.
Means of log transformed biomarkers were compared in symptomatic vs
asymptomatic cohorts using 2-sample t-tests. Analyses were adjusted for
stratum sampling weights.
Results: In the symptomatic and asymptomatic cohorts, 56.3% and 56.5%
were female, mean age was 56.7 and 54.6 years, mean BMI was 26.5 and
25.4, respectively. MRI abnormalities ≥ grade 1 were seen in 91% of symp-
tomatic and 67.5% of asymptomatic subjects. No signiﬁcant differences in
biomarker levels in asymptomatic vs symptomatic cohorts were seen for
adiponectin, CTX-I, MMP-1, MMP-3, COMP and HA (Table 1). Statistically
Table 1. Mean (SD) of select log-transformed serum biomarkers in symptomatic and
asymptomatic cohorts
Biomarker Symptomatic cohort Asymptomatic cohort p-value
(n=255) (n=80)
Adiponectin 3.08 (0.36) 3.01 (1.30) 0.47
CRP 1.76 (0.79) 1.31 (2.30) 0.009
CTX-I -1.41 (0.36) -1.23 (1.35) 0.05
IL-4 2.65 (1.58) -3.54 (2.89) <0.001
IL-10 1.25 (1.25) -2.45 (2.71) <0.001
IL-1b 0.20 (0.84) -2.62 (1.75) <0.001
MMP-1 2.85 (0.39) 2.72 (1.18) 0.15
MMP-3 2.59 (0.27) 2.68 (1.08) 0.21
MMP-9 5.67 (0.28) 6.00 (0.82) <0.001
Resistin 2.23 (0.26) 3.10 (0.73) <0.001
TIMP-1 5.13 (0.13) 5.01 (0.32) <0.001
TNF alpha 2.54 (0.66) -2.59 (0.69) <0.001
COMP 7.39 (0.11) 7.36 (0.51) 0.36
HA 3.61 (0.41) 3.63 (1.27) 0.83
signiﬁcant differences were seen for all other biomarkers, including CRP,
eotaxin, interleukins, MMP-9, TIMP-1, TNF alpha, resistin and chemokines.
Conclusions: Serum biomarkers for inﬂammation, especially involving pro-
inﬂammatory and regulatory cytokines, are the key distinguishing feature
between those with symptomatic knee pain and those without. This sug-
gests that alterations in innate immunity are associated with persistent
knee pain, in view of the absence of convincing evidence in the literature
for adaptive immunity in OA.
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Purpose: Aggrecanase cleavage at the Glu-Ala bond in the interglobular
domain of aggrecan, releasing N-terminal ARGS fragments, is an early key
event in arthritis and joint injuries. We have previously shown that synovial
ﬂuid levels of ARGS (SF ARGS) are elevated early after knee injury and in
arthritis. Here we investigate whether SF ARGS levels distinguish subjects
with progressive radiographic knee osteoarthritis (ROA) from those with
stable or no ROA.
Methods: We studied 141 subjects whom at examination A had undergone
meniscectomy some 18 years earlier. Seventeen un-operated individuals
without injury to the meniscus or ligaments were used as references. At
examinations A and B, with a mean follow up time of 7.5 years, we obtained
SF and standing tibiofemoral and skyline patellofemoral radiographs. SF
ARGS was measured by a sandwich immunosorbent electrochemilumines-
cence assay using an anti-aggrecan antibody (AHP0022; Invitrogen) for
capture, and a monoclonal anti-ARGS (OA-1) for detection. Radiographs
were graded according to the OARSI atlas. The association between levels
of SF ARGS at examination A and progression of radiographic features
of knee OA between examinations A and B were assessed using logistic
regression with or without adjustments for age, gender, BMI, and time
between examinations A and B.
Results: The levels of SF ARGS 18 years after meniscectomy ranged from
0.15 to 15.07 pmol/ml (mean 6.95 pmol/ml), were no different from levels
in un-operated individuals, and were unrelated to radiographic status at
examination A. A weak negative association was found between levels of SF
ARGS and loss of joint space: The likelihood of progression of radiographic
Table 1. Association of SF ARGS at examination A and progression of radiographic features
of OA from examination A to examination B 7.5 years later. Odds ratios (95% CI) adjusted
for age, gender, BMI and time between examinations A and B
Radiographic feature Total sample, Stratiﬁed for absence or presence
n=141 of ROA at examination A
No ROA, n=63 ROA, n=78
JSN 0.89 (0.79-0.996)* 0.77 (0.62-0.95)* 0.96 (0.81-1.13)
Osteophyte 0.97 (0.87-1.09) 0.92 (0.76-1.11) 0.99 (0.86-1.15)
ROA (JSN and/or Osteophyte) 0.89 (0.78-1.02) 0.87 (0.72-1.04) 0.91 (0.73-1.13)
*P<0.05.
